Claudia Proto - Concepedia

Author

Claudia Proto

Fondazione IRCCS Istituto Nazionale dei Tumori ORCID

Also Known As

A Achilli, C Proto, C. Proto, Claudia Proto, Filippo de Marinis

290

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

Fondazione IRCCS Istituto Nazionale dei Tumori University of Milan Istituti di Ricovero e Cura a Carattere Scientifico Mario Negri Institute for Pharmacological Research Humanitas University

About

Claudia Proto is an author at Fondazione IRCCS Istituto Nazionale dei Tumori specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	27	1.4K
2	Health Sciences	3	3	180
3	Engineering	1	1	31
4	Public Health	1	1	11
5	Cell Biology	1	1	17

Claudia Proto

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade Giuseppe Lo Russo, Massimo Moro, Michele Sommariva, Clinical Cancer Research	2018	400
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors Giovanni Fucà, Giulia Galli, M. Poggi, ESMO Open	2019	203
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer Lucio Crinò, Giuseppe Bronte, Paolo Bidoli, Lung Cancer Neuro-oncologyBrain MetastasesMedicineBronchial NeoplasmCancer Treatment	2019	154
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status Francesco Facchinetti, Giulia Mazzaschi, Fausto Barbieri, European Journal of Cancer First-line PembrolizumabMedicinePathologyImmune Checkpoint InhibitorPoor Performance Status	2020	145
Use of nivolumab in elderly patients with advanced squamous non–small-cell lung cancer: results from the Italian cohort of an expanded access programme Francesco Grossi, Lucio Crinò, Antonio Logroscino, European Journal of Cancer Expanded Access ProgrammeGeriatric OncologyCancer EpidemiologyElderly PatientsGeriatrics	2018	108
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% Alessio Cortellini, Marcello Tiseo, Giuseppe Luigi Banna, Cancer Immunology Immunotherapy Advanced NsclcOncologyFirst-line Pembrolizumab EffectivenessPd-l1 ExpressionImmune Checkpoint Inhibitor	2020	87
CONTROLLED TRIAL OF STREPTOKINASE AND HEPARIN IN ACUTE MYOCARDIAL INFARCTION N Dioguardi, A Lotto, Guido Levi, The Lancet ThrombosisCardiovascular DiseaseAtherosclerosisPlatelet AntagonistMedicine	1971	85
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes Alessio Cortellini, Alex Friedlaender, Giuseppe Luigi Banna, Clinical Lung Cancer Pd-l1 ExpressionClinical EpidemiologyImmunologyImmune Checkpoint InhibitorClinical Outcomes	2020	82
Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study Mattia Boeri, Massimo Milione, Claudia Proto, Clinical Cancer Research	2019	81
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort Arsela Prelaj, Roberto Ferrara, Sara Elena Rebuzzi, Cancers ImmunologyImmunotherapeuticsImmunotherapyOncologyDeath Ligand 1	2019	77

Page 1